Literature DB >> 17531080

Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.

F Fierro1, T Illmer, D Jing, E Schleyer, G Ehninger, S Boxberger, M Bornhäuser.   

Abstract

OBJECTIVES: Recent data show that Imatinib mesylate (IM) also affects haematopoietic stem cells (HSC), T lymphocytes and dendritic cells that do not harbour constitutively active tyrosine kinases.
MATERIALS AND METHODS: We evaluated possible effects of IM on human bone marrow-derived mesenchymal stem cells (MSC) in vitro.
RESULTS: Screening the activity of 42 receptor tyrosine kinases revealed an exclusive inhibition of platelet-derived growth factor receptorbeta (PDGFRbeta). Analysis of downstream targets of PDGFRbeta demonstrated IM-mediated reduction of Akt and Erk1/2 phosphorylation. Culture of MSC with IM led to the reversible development of perinuclear multi-vesicular bodies. The proliferation and clonogenicity of MSC were significantly reduced compared to control cultures. IM favoured adipogenic differentiation of MSC whereas osteogenesis was suppressed. The functional deficits described led to a 50% reduction in the support of clonogenic haematopoietic stem cells, cultured for 1 month on a monolayer of MSC with IM.
CONCLUSION: In summary, inhibition of PDGFRbeta and downstream Akt and Erk signalling by IM has a significant impact on proliferation and differentiation of human MSC in vitro.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531080      PMCID: PMC6496321          DOI: 10.1111/j.1365-2184.2007.00438.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  30 in total

1.  Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation.

Authors:  Irina Kratchmarova; Blagoy Blagoev; Mandana Haack-Sorensen; Moustapha Kassem; Matthias Mann
Journal:  Science       Date:  2005-06-03       Impact factor: 47.728

2.  Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.

Authors:  Martin Bornhäuser; Nicolaus Kröger; Rainer Schwerdtfeger; Karin Schafer-Eckart; Herbert G Sayer; Christoph Scheid; Mattias Stelljes; Joachim Kienast; Peter Mundhenk; Stefan Fruehauf; Michael G Kiehl; Hannes Wandt; Catrin Theuser; Gerhard Ehninger; Axel R Zander
Journal:  Eur J Haematol       Date:  2006-01       Impact factor: 2.997

3.  Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.

Authors:  E M Horwitz; D J Prockop; L A Fitzpatrick; W W Koo; P L Gordon; M Neel; M Sussman; P Orchard; J C Marx; R E Pyeritz; M K Brenner
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

4.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

Review 5.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells.

Authors:  Wei Zhang; Hui Tu Liu
Journal:  Cell Res       Date:  2002-03       Impact factor: 25.617

6.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

7.  Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages.

Authors:  M K Majumdar; M A Thiede; S E Haynesworth; S P Bruder; S L Gerson
Journal:  J Hematother Stem Cell Res       Date:  2000-12

8.  Effects of imatinib on bone marrow engraftment in syngeneic mice.

Authors:  J Hoepfl; C Miething; R Grundler; K S Götze; C Peschel; J Duyster
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

9.  P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.

Authors:  T Illmer; M Schaich; U Platzbecker; J Freiberg-Richter; U Oelschlägel; M von Bonin; S Pursche; T Bergemann; G Ehninger; E Schleyer
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

10.  Mesenchymal stem cells can be differentiated into endothelial cells in vitro.

Authors:  Joachim Oswald; Sabine Boxberger; Birgitte Jørgensen; Silvia Feldmann; Gerhard Ehninger; Martin Bornhäuser; Carsten Werner
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

View more
  33 in total

1.  Mesenchymal stem cells or cardiac progenitors for cardiac repair? A comparative study.

Authors:  Remco Koninckx; Annick Daniëls; Severina Windmolders; Françoise Carlotti; Urbain Mees; Paul Steels; Jean-Luc Rummens; Marc Hendrikx; Karen Hensen
Journal:  Cell Mol Life Sci       Date:  2010-10-24       Impact factor: 9.261

2.  Mesenchymal Stem Cells Sense Three Dimensional Type I Collagen through Discoidin Domain Receptor 1.

Authors:  A W Lund; J P Stegemann; G E Plopper
Journal:  Open Stem Cell J       Date:  2009

3.  Gelatinous transformation of bone marrow following the use of dasatinib in a patient with philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Sanjeev Kumar Sharma; Dharma Choudhary; Anil Handoo; Gaurav Kharya; Nitin Gupta; Punita Pavecha; Ritu Chadha
Journal:  Leuk Res Rep       Date:  2013-01-07

4.  Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro.

Authors:  Lysann Michaela Kroschwald; Josephine Tabea Tauer; Sonja Ingrid Kroschwald; Meinolf Suttorp; Anne Wiedenfeld; Stefan Beissert; Andrea Bauer; Martina Rauner
Journal:  Oncol Lett       Date:  2019-06-21       Impact factor: 2.967

5.  Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway.

Authors:  Jie Yu Ye; Godfrey Chi Fung Chan; Liang Qiao; Qizhou Lian; Fan Yi Meng; Xue Qun Luo; Levon M Khachigian; Ming Ma; Ruixia Deng; Jian Liang Chen; Beng H Chong; Mo Yang
Journal:  Haematologica       Date:  2010-06-18       Impact factor: 9.941

Review 6.  Growth factor regulation of proliferation and survival of multipotential stromal cells.

Authors:  Melanie Rodrigues; Linda G Griffith; Alan Wells
Journal:  Stem Cell Res Ther       Date:  2010-10-26       Impact factor: 6.832

7.  Inhibition of ERK promotes collagen gel compaction and fibrillogenesis to amplify the osteogenesis of human mesenchymal stem cells in three-dimensional collagen I culture.

Authors:  Amanda W Lund; Jan P Stegemann; George E Plopper
Journal:  Stem Cells Dev       Date:  2009-03       Impact factor: 3.272

8.  Reversing bone loss by directing mesenchymal stem cells to bone.

Authors:  Wei Yao; Min Guan; Junjing Jia; Weiwei Dai; Yu-An E Lay; Sarah Amugongo; Ruiwu Liu; David Olivos; Mary Saunders; Kit S Lam; Jan Nolta; Diana Olvera; Robert O Ritchie; Nancy E Lane
Journal:  Stem Cells       Date:  2013-09       Impact factor: 6.277

9.  Agonism of Wnt-β-catenin signalling promotes mesenchymal stem cell (MSC) expansion.

Authors:  Michael D Hoffman; Danielle S W Benoit
Journal:  J Tissue Eng Regen Med       Date:  2013-04-01       Impact factor: 3.963

10.  Xeno-Free Extraction, Culture, and Cryopreservation of Human Adipose-Derived Mesenchymal Stem Cells.

Authors:  Carlos Hugo Escobar; Orlando Chaparro
Journal:  Stem Cells Transl Med       Date:  2016-02-02       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.